271results about How to "Avoid management" patented technology

The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and / or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

The invention relates to a radioactive source automatic supervision and real-time monitoring method and a system. The method mainly comprises the following steps: a positioning terminal in which a GPS positioning unit and a CDMA network positioning unit are arranged and source file information is solidified is arranged on a radioactive source; the source file information is stored in a network server of a monitoring center and a source admission range is set up; source position information and source file information is acquired at real time and corresponding source information in the network serve is updated at real time; when the source information stored in the network server changes, the monitoring center automatically obtains prompting information and judges whether the change of the source information is beyond the admission range; when the change of the source information exceeds the admission range, automatic alarm is carried out. The system realizing the method comprises a positioning terminal assembly device, a source information storing device, a source information updating device, a source information monitoring device and a real-time alarm device. The method and the system realize automatic supervision and real-time monitoring of all links of the radioactive source, thereby putting an end to severe security accidents like loss of the radioactive source, etc.

The invention discloses a method and a system for protecting a condition privacy of an internet of vehicles based on certificateless batch verification. The method comprises the following steps: a key generation center KGA and a track authentication center TRA jointly generate a master key and a system parameter of the internet of vehicles; according to the system parameter and vehicle user real identity information, the TRA generates a pseudonym identity of a vehicle user; the KGC generates a partial private key of the vehicle user; the vehicle user generates an own key; the vehicle user signs a message; an RSU carries out verification on a signature; and the RSU carries out the batch verification on the signature. According to the method and the system disclosed by the invention, by adopting a certificateless cryptography system, the unsolvable inherent certificate management problem and the certificate maintenance problem in the traditional public key cryptography system are effectively solved; and meanwhile, the key escrow problem caused by an identity-based cryptography system is also avoided; by adopting a batch verification technology, the signature verification efficiency in the internet of vehicles is improved; and in the internet of vehicles, the key generation center KGA and the track authentication center TRA are adopted to realize the condition privacy protection on the internet of vehicles.

The present invention provides methods for preventing, managing, treating and / or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and / or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and / or LRI), and / or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and / or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and / or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life. In particular embodiments the methods of the invention comprising administering to subject an effective amount of one or more modified antibodies that immunospecifically bind to one or more RSV antigens with an association rate (kon) of at least 2×105 M−1s−1 and a dissociation rate (koff) of less than 5×10−4 s−1.

The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and / or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The biomarkers of the invention may be utilized to diagnose arthritis, differentiate between two stages of osteoarthritis and diagnose a particular stage of osteoarthritis. The invention provides kits comprising polynucleotides and / or proteins which specifically and / or selectively hybridize to the products of the biomarkers of the invention. Such kits are useful in diagnosing arthritis, differentiating between two stages of osteoarthritis, diagnosing a particular stage of osteoarthritis monitoring disease progression, and monitoring the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.

The invention discloses an administration mechanism for a standard way access control list (ACL) under an IPsec (internet protocol security) protocol, which belongs to the data communication field. The method is characterized in that address information in the standard way ACL rule is divided into a paragraph code and a segment code, a rule index of the standard way ACL rule is defined, administration of the standard way ACL rule is divided into two independent parts, i.e., source address range rule index and destination address range rule index, and the administration of the standard way ACL rule is performed in the same binary tree data structure. A data structure involved by the method comprises three parts including a binary tree, a segment code link table and a rule index digit group. The administration mechanism has the remarkable characteristics that for the standard way ACL rule with any address range, overlapped address range and multilevel address range, convenience and rapidness in operations of addition, searching and deletion can be realized, and the system expenditure is small.

An embodiment of a safety helmet ( 100 ) for protecting the human head against repetitive impacts, moderate impacts and severe impacts so as to significantly reduce the likelihood of both translational and rotational brain injury and concussions includes an outer shell ( 106 ), an outer liner ( 102 ) disposed within and coupled to the outer shell, and an inner liner ( 104 ) disposed within and coupled in spaced opposition to the outer liner by a plurality of isolation dampers ( 108 ) for omnidirectional movement of the inner liner relative to the outer liner and the outer shell.

Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.